prednisone has been researched along with abiraterone in 96 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 67 (69.79) | 24.3611 |
| 2020's | 29 (30.21) | 2.80 |
| Authors | Studies |
|---|---|
| Anand, A; Bubley, GJ; Danila, DC; de Bono, JS; Denmeade, SR; Fleisher, M; Haqq, C; Kheoh, T; Koscuiszka, M; Larson, SM; Molina, A; Morris, MJ; Ryan, CJ; Scher, HI; Schwartz, LH; Smith, MR; Taplin, ME | 1 |
| Petrylak, DP | 1 |
| Thompson, CA | 1 |
| Bianchini, D; Cheng, T; Chi, KN; Chieffo, N; Chu, L; de Bono, JS; Efstathiou, E; Ellard, SL; Fizazi, K; Flaig, TW; Fléchon, A; Goodman, OB; Hainsworth, JD; Haqq, CM; Harland, S; Hutson, TE; Jones, RJ; Kheoh, T; Logothetis, CJ; Loriot, Y; Mainwaring, P; Molina, A; North, S; Patterson, H; Ryan, CJ; Saad, F; Saleh, M; Scher, HI; Scholz, M; Staffurth, JN; Sternberg, CN; Zivi, A | 1 |
| Antonarakis, ES; Eisenberger, MA | 1 |
| Beltran, H; Tagawa, ST | 1 |
| Berruti, A; Pia, A; Terzolo, M | 1 |
| Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M | 1 |
| Di Bisceglie, M; Moraca, L; Romito, S; Sasso, N; Sepede, C; Suriano, A; Turitto, G | 1 |
| Shah, BK; Shrestha, S | 1 |
| Pal, SK; Sartor, O | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Francini, F; Laera, L; Paganini, G; Perrella, A; Petrioli, R; Roviello, G | 1 |
| Li, B; Liu, SX; Xia, J; Zhang, TS; Zhou, ZR | 1 |
| Chandler, DW; Haqq, CM; Kheoh, T; Molina, A; Peng, W; Ryan, CJ; Scher, HI; Welkowsky, E | 1 |
| Al-Asaaed, S; Winquist, E | 1 |
| Hoffman-Censits, J; Kelly, WK | 1 |
| Aebersold, D; Attard, G; Cassoly, E; Clarke, NW; de Bono, JS; Dearnaley, DP; James, ND; Mason, MD; Matheson, D; Millman, R; Parker, CC; Parmar, MK; Ritchie, AW; Russell, JM; Schiavone, F; Spears, MR; Sydes, MR; Thalmann, G | 1 |
| Bellmunt, J; de Bono, JS; Efstathiou, E; Kheoh, T; Li, J; Loriot, Y; Molina, A; Montgomery, B; Ryan, CJ; Scher, HI; Tran, N | 1 |
| Altavilla, A; Attard, G; de Bono, J; Dearnaley, D; Ferraldeschi, R; Gillessen, S; Lorente, D; Mateo, J; Omlin, A; Parker, C; Perez, R; Pezaro, C; Tunariu, N; Zafeirou, Z | 1 |
| Auchus, RJ; Mundle, SD; Nguyen, S; Yu, MK | 1 |
| Dahut, WL; Madan, R | 1 |
| Carles, J; de Bono, JS; De Porre, P; de Souza, P; Fizazi, K; Flaig, TW; Griffin, TW; Higano, CS; Kheoh, T; Li, J; Logothetis, CJ; Miller, K; Molina, A; Mulders, PF; Naini, V; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Sternberg, CN; Taplin, ME; Yu, MK | 1 |
| Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T | 1 |
| Ndibe, C; Sonpavde, G; Wang, CG | 1 |
| Cho, E; Dalkin, BL; Konodi, MA; Kurland, BF; Liao, JJ; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Russell, KJ | 1 |
| Moore, A; Moore, DC | 1 |
| Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA | 1 |
| Abbott, DH; Bird, IM | 1 |
| Baeten, K; Bianchini, D; Crespo, M; Danila, DC; de Bono, JS; Figueiredo, I; Fleisher, M; Flohr, P; Kheoh, T; Lorente, D; Mateo, J; McCormack, R; Miranda, S; Molina, A; Olmos, D; Scher, HI; Seed, G; Terstappen, LW | 1 |
| Gschwend, J; Miller, K; Wolff, JM | 1 |
| Cristofanilli, M; Hoffman-Censits, JH; Kelly, WK; Kennedy, B; Kilpatrick, D; Leiby, B; Lewis, N; Lin, J; Mu, Z; Patel, SA; Sama, AR; Yang, H; Ye, Z | 1 |
| Aggarwal, RR; Alumkal, JJ; Alyamani, M; Anantharaman, A; Beer, TM; Dittamore, R; Fong, L; Friedlander, TW; Graff, JN; Huang, Y; Kim, W; Lin, AM; Paris, PL; Paz, R; Premasekharan, G; Russell, C; Ryan, CJ; Sharifi, N; Small, EJ; Zejnullahu, K; Zhang, L | 1 |
| Gschwend, J; Miller, K; Ohlmann, CH | 1 |
| Black, PC; Struss, WJ | 1 |
| Agarwal, N; Hahn, AW; Hale, P; Rathi, N | 1 |
| Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A | 1 |
| Figg, WD; Madan, RA; Schmidt, KT | 1 |
| Attard, G; Linch, M | 1 |
| Albany, C; Antonarakis, ES; Cao, X; Caram, MV; Chinnaiyan, AM; Cooney, KA; Corn, PG; Daignault-Newton, S; Feng, FY; Hussain, M; Knudsen, KE; Kunju, LP; Lonigro, RJ; Mehra, R; Montgomery, B; Robinson, D; Shevrin, DH; Siddiqui, J; Smith, DC; Stadler, WM; Stein, MN; Tomlins, SA; Twardowski, PW; Whang, YE; Wu, YM | 1 |
| Cai, W; Chi, C; Dong, B; Fan, L; Pan, J; Qian, H; Shangguan, X; Shao, X; Wang, R; Wang, Y; Xu, F; Xue, W; Zhang, Y; Zhou, L; Zhu, Y | 1 |
| Taneja, SS | 1 |
| Elkon, JM; Lin, J; Millado, KF; Millett, RL | 1 |
| Chen, J; Dai, Y; Gao, Q | 1 |
| Carthon, B; Chiong, E; Figg, WD; Fishkin, P; Harvey, RD; Ibraheem, A; Karrison, T; Kozloff, MF; Martinez, E; Nabhan, C; Peer, CJ; Ratain, MJ; Stadler, WM; Szmulewitz, RZ; Yong, WP | 1 |
| Bianchini, D; Crespo, M; de Bono, JS; Dolling, D; Figueiredo, I; Flohr, P; Lorente, D; Mateo, J; Miranda, S; Olmos, D; Scher, HI; Seed, G; Terstappen, LWMM | 1 |
| Barret, E; Bennamoun, M; Bonnetain, F; Cathala, N; Cathelineau, X; Charton, E; Fenioux, C; Henriques, J; Joulia, ML; Louvet, C; Molitor, JL; Mombet, A; Prapotnich, D; Ropert, S; Rozet, F; Sanchez-Salas, R | 1 |
| Attard, G; Castro, E; Cendón, Y; Correa, R; Cruz, JJ; Garcés, T; Grau, G; Gutierrez-Pecharoman, A; Herrera, B; Jayaram, A; López, PP; López-Campos, F; Lorente, D; Lozano, R; Montesa, A; Nombela, MP; Olmos, D; Pacheco, MI; Rivera, L; Romero-Laorden, N; Rosero, A; Saez, MI; Van de Poll, F; Villatoro, R | 1 |
| Barata, PC; Edwin, NC; Emamekhoo, H; Garcia, JA; Grivas, P; Woo, KM | 1 |
| Scher, HI; Teo, MY | 1 |
| Chi, KN; Eigl, BJ; Finch, DL; Gleave, ME; Ivanov, N; Khalaf, DJ; Kollmannsberger, CK; Oja, C; Sunderland, K; Vergidis, J; Zulfiqar, M | 1 |
| Morgans, AK; Ryan, CJ | 1 |
| Berruti, A; Dalla Volta, A; Formenti, AM | 1 |
| Bubley, GJ; Calagua, C; Chang, P; Chang, SL; Ellis, WJ; Harshman, LC; Kibel, AS; Lin, DW; Lis, R; McKay, RR; Montgomery, B; Pienta, KJ; Ross, AE; Taplin, ME; Trinh, QD; Wagner, AA; Xie, W; Ye, H; Zhang, Z | 1 |
| Miller, K | 1 |
| Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D | 1 |
| Hindié, E; Morgat, C | 1 |
| Bedussi, F; Berruti, A; Buttigliero, C; Dalla Volta, A; Ferrari, L; Pia, A; Roca, E; Sigala, S; Tucci, M; Vittorio Scagliotti, G | 1 |
| Dubinsky, S; Emmenegger, U; McFarlane, TRJ; McLeod, AG; Thawer, A | 1 |
| Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP | 1 |
| Armstrong, CM; Cai, D; Chen, J; Chen, N; Dai, J; Guo, W; Liu, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Yin, X; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhao, P; Zhu, S; Zhu, X | 1 |
| Baloch, HM; Grice-Patil, ZJ; Hoang, TD; Mai, VQ; Selig, DJ; Shakir, MK | 1 |
| Aebersold, DM; Ali, A; Attard, G; Brawley, CD; Chowdhury, S; Clarke, NW; Cook, A; Cross, WR; de Bono, JS; Dearnaley, DP; Douis, H; Gillessen, S; Gilson, C; Hoyle, AP; Ingleby, F; James, ND; Jones, RJ; Mason, MD; Matheson, D; Millman, R; Parker, CC; Parmar, MKB; Ritchie, AWS; Russell, M; Sydes, MR | 1 |
| Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
| Karaağaç, M; Karakurt Eryılmaz, M | 1 |
| Corona, SP; D'Angelo, A; Roviello, G; Sobhani, N | 1 |
| Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
| Beriwal, S; Rodríguez-López, JL | 1 |
| Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M | 1 |
| Alyamani, M; Auchus, RJ; O'Day, P; Sharifi, N; Wright, C | 1 |
| Baser, O; George, DJ; Huang, A; Lechpammer, S; Mardekian, J; Ramaswamy, K; Sandin, R; Schultz, NM; Wang, L | 1 |
| Carretero-González, A; Castellano, D; de Velasco, G; Lora, D; Lorente, D; Manneh, R | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Csuk, R; Hoenke, S; Serbian, I | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
| Chang, EM; Deville, C; Feng, FY; Kishan, AU; Koontz, BF; Nickols, NG; Ost, P; Parikh, NR; Phillips, R; Raldow, AC; Reiter, RE; Rettig, MB; Spratt, DE; Steinberg, ML; Tran, PT; Vapiwala, N | 1 |
| Allman, K; Barata, P; Fallah, J; Garcia, JA; Gilligan, TD; Gupta, R; Li, H; Martin, A; Ornstein, MC; Rini, BI; Sheng, IY | 1 |
| Aparicio, A; Araujo, JC; Boukovala, M; Corn, PG; Efstathiou, E; Hoang, A; Kim, J; Logothetis, CJ; Pagliaro, L; Spetsieris, N; Subudhi, SK; Tannir, NM; Troncoso, P; Tsikkinis, A; Tu, SM; Wang, J; Wang, X; Weldon, JA; Wen, S; Zurita, AJ | 1 |
| Amaravadi, R; Black, TA; Buckingham, TH; Calara-Nielsen, K; Carpenter, EL; Cherkas, Y; Foulk, B; Gross, S; Haas, NB; He, M; Jones, JO; LaRiviere, MJ; Long, Q; Majmundar, KJ; Min, EJ; Pal, SK; Patel, J; Savitch, SL; Smirnov, D; Vaughn, DJ; Wellen, KE; Yee, SS | 1 |
| Agarwal, N; Dall'Era, M; Evans, CP; Gao, AC; Lara, PN; Liu, C; Pan, CX; Parikh, M; Robles, D; Wu, CY | 1 |
| Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E | 1 |
| Bratt, O; Fode, M; Kistorp, C; Klausen, TW; Lindberg, H; Nolsøe, AB; Palapattu, G; Sønksen, J; Ternov, KK; Østergren, PB | 1 |
| Annala, M; Azad, AA; Bacon, JVW; Beja, K; Chi, KN; Ferrario, C; Fu, S; Gingerich, JR; Hotte, SJ; Iqbal, N; Kallio, HML; Khalaf, DJ; Lo, G; North, SA; Nykter, M; Ong, M; Pezaro, CJ; Ruether, JD; Schönlau, E; Sipola, J; Sridhar, SS; Taavitsainen, S; Tran, B; Vandekerkhove, G; Wadhwa, D; Wong, A; Wood, LA; Wyatt, AW | 1 |
| Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
| Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Xiong, X; Xu, H; Yang, L; Yi, X | 1 |
| Balk, SP; Cheng, HH; Chew, F; Kantoff, PW; Kolokythas, O; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Nelson, PS; Schweizer, MT; Sharifi, N; Taplin, ME; Yu, EY | 1 |
| Benoist, GE; Boerrigter, E; Donders, R; Mehra, N; Overbeek, JK; Ter Heine, R; van Erp, NP; van Oort, IM | 1 |
| Abadie-Lacourtoisie, S; Berdah, JF; Berthold, D; Bossi, A; Calabro, F; Carles, J; Chand-Fouche, ME; El Kouri, C; Escande, A; Fizazi, K; Fléchon, A; Foulon, S; Freixa, SV; Gravis, G; Hasbini, A; Jamaluddin, M; Kacso, G; Laguerre, B; Latorzeff, I; Magne, N; Martin, E; McDermott, R; Mourey, L; Priou, F; Rieger, I; Ronchin, P; Rosello, A; Roubaud, G; Schlurmann, F; Silva, M; Supiot, S; Thiery-Vuillemin, A; Tombal, B | 1 |
| Cintra, MTG; Costa, AL; de Almeida, DCB; de Carvalho, FB; de Oliveira Faria, BL | 1 |
| Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P | 1 |
| Bhargava, V; Bryce, AH; Carlson, RE; Dehm, SM; Gormley, M; Hillman, DW; Jimenez, RE; Kalari, KR; Kohli, M; Li, Y; Qin, S; Sicotte, H; Sinnwell, JP; Tan, W; Vedell, PT; Wang, L; Weinshilboum, RM | 1 |
| Basu, A; Carlson, JJ; Garrison, LP; Jiao, B; Nyame, YA | 1 |
| Bracarda, S; Chen, G; Chi, KN; de Bono, J; Garcia, J; Harris, A; Hinton, H; Massard, C; Matsubara, N; Olmos, D; Sandhu, S; Sane, R; Schenkel, F; Sternberg, CN; Sweeney, C | 1 |
| Chen, T; Ding, J; Gu, T; Li, J; Zhu, Q | 1 |
| Antonarakis, ES; Armstrong, AJ; Beltran, H; Beumer, JH; Bobek, O; Bryce, AH; Goldkorn, A; Hahn, O; Halabi, S; Heller, G; Hillman, DW; Langevin, B; Lewis, LD; McGary, EC; Mehan, PT; Morris, MJ; Roth, BJ; Ryan, C; Schwartz, L; Small, EJ; Taplin, ME; Watt, C; Xiao, H | 1 |
18 review(s) available for prednisone and abiraterone
| Article | Year |
|---|---|
Current clinical trials in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
[Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Drug Resistance, Neoplasm; Humans; Male; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2012 |
Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Humans; Kallikreins; Male; Placebos; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2014 |
Secondary hormonal manipulation in castration resistant prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Drug Therapy, Combination; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2014 |
Practical guide to the use of enzalutamide.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Humans; Male; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Treatment Outcome | 2014 |
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2014 |
Corticosteroids in the management of prostate cancer: a critical review.
Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Topics: Adrenal Hyperplasia, Congenital; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Male; Naphthalenes; Prednisone; Prostate; Prostatic Neoplasms; Protective Factors; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
[Strategies for First-Line Treatment of mCRPC].
Topics: Androstenes; Benzamides; Drug Therapy, Combination; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2016 |
Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Humans; Male; Neoplasms, Hormone-Dependent; Patient Selection; Prednisolone; Prednisone; Prostatic Neoplasms; Treatment Outcome | 2017 |
[Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)].
Topics: Androstenes; Antineoplastic Agents, Hormonal; Humans; Male; Prednisone; Prostatic Neoplasms | 2019 |
Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone.
Topics: Androstenes; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Interactions; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies; Thrombosis; Treatment Outcome | 2019 |
Recognition and Treatment of Adrenal Insufficiency Secondary to Abiraterone: A Case Report and Literature Review.
Topics: Adrenal Insufficiency; Aged; Androstenes; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2019 |
Corticosteroid switch after progression on abiraterone acetate plus prednisone.
Topics: Abiraterone Acetate; Adrenal Cortex Hormones; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Middle Aged; Patient Selection; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Grading; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
Topics: Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2021 |
Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
27 trial(s) available for prednisone and abiraterone
| Article | Year |
|---|---|
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Glucocorticoids; Humans; Hyperaldosteronism; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Fatigue; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Survival Analysis; Treatment Outcome | 2011 |
Androgen dynamics and serum PSA in patients treated with abiraterone acetate.
Topics: Abiraterone Acetate; Androgens; Androstenes; Double-Blind Method; Humans; Kallikreins; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome | 2014 |
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytochrome P-450 Enzyme Inhibitors; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms; Research Design; Steroid 17-alpha-Hydroxylase; Switzerland; Treatment Outcome; United Kingdom | 2014 |
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids | 2015 |
[Recruiting participants - study of therapy of CRPC].
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Biomarkers, Tumor; Disease Progression; Drug Therapy, Combination; Germany; Gonadotropin-Releasing Hormone; Humans; Male; Patient Selection; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2014 |
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Topics: Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2015 |
External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
Topics: Androgen Antagonists; Androgens; Androstenes; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoadjuvant Therapy; Prednisone; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Time Factors | 2015 |
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Testosterone | 2016 |
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
Topics: Aged; Androstenes; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2017 |
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; DNA Repair; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-ets; Receptors, Androgen | 2018 |
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Fasting; Food; Glucocorticoids; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Singapore; Testosterone; Treatment Outcome; United States | 2018 |
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2018 |
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Dexamethasone; Disease Progression; Humans; Male; Middle Aged; Oncogene Proteins, Fusion; Pilot Projects; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Receptors, Androgen; Survival Analysis; Treatment Outcome | 2018 |
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2019 |
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Humans; Kallikreins; Leuprolide; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm, Residual; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; United States | 2019 |
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2019 |
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Sunitinib; Treatment Outcome; Tumor Microenvironment | 2021 |
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niclosamide; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2021 |
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Middle Aged; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thiohydantoins | 2021 |
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
Topics: Adrenal Cortex; Adult; Aged; Aged, 80 and over; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Correlation of Data; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Female; Humans; Hypertension; Male; Prednisone; Prostatic Neoplasms | 2022 |
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Pain; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone | 2022 |
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Exanthema; Humans; Hyperglycemia; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
51 other study(ies) available for prednisone and abiraterone
| Article | Year |
|---|---|
FDA approves prostate cancer treatment that inhibits testosterone synthesis.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Drug Approval; Humans; Male; Prednisone; Prostatic Neoplasms; Testosterone; United States; United States Food and Drug Administration | 2011 |
Expanding treatment options for metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase | 2011 |
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Adrenocorticotropic Hormone; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2011 |
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Topics: Androstenes; Androstenols; Drug Interactions; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms | 2012 |
Durable complete remission with abiraterone in castration resistant metastatic prostate cancer.
Topics: Adenocarcinoma; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Castration; Humans; Lymphatic Metastasis; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction | 2013 |
Abiraterone and its place in the treatment of metastatic CRPC.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Drug Therapy, Combination; Humans; Male; Mineralocorticoids; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase | 2014 |
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Anti-Inflammatory Agents; Dexamethasone; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2014 |
Abiraterone's efficacy confirmed; time to aim higher.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Bone Neoplasms; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2015 |
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Abiraterone-induced rhabdomyolysis: A case report.
Topics: Analgesics, Opioid; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Constipation; Creatine Kinase; Cytochrome P450 Family 17; Drug Therapy, Combination; Humans; Injections, Spinal; Male; Middle Aged; Morphine; Nausea; Pain Management; Prednisone; Prostatic Neoplasms, Castration-Resistant; Rhabdomyolysis; Vomiting | 2017 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Clinical Trials as Topic; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant | 2016 |
[Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Humans; Male; Medical Oncology; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms; Treatment Outcome; Urology | 2017 |
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2017 |
Expanding the use of abiraterone in prostate cancer: Is earlier always better?
Topics: Androstenes; Castration; Humans; Male; Prednisone; Prostatic Neoplasms | 2018 |
Prostate cancers that 'Wnt' respond to abiraterone.
Topics: Abiraterone Acetate; Androstenes; Cell Cycle; Cell Proliferation; Genome-Wide Association Study; Humans; Male; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Wnt Signaling Pathway | 2018 |
Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2018 |
Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Androstenes; Castration; Humans; Male; Prednisone; Prostatic Neoplasms | 2018 |
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Prostate cancer involving bilateral seminal vesicles along with bone and testicular metastases: a case report.
Topics: Adenocarcinoma; Aged; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Bone Neoplasms; Humans; Male; Neoplasm Grading; Orchiectomy; Physical Examination; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Seminal Vesicles; Testicular Neoplasms; Tomography, X-Ray Computed | 2018 |
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Dexamethasone; Disease Progression; Drug Substitution; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2018 |
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Glucocorticoids; Humans; Male; Pilot Projects; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2018 |
Hard Problems Need "Soft" Science: Integrating Quality of Life into Treatment Decision Making.
Topics: Androstenes; Benzamides; Decision Making; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2019 |
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Fractures, Bone; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2019 |
Early use of abiraterone and radium-223 in metastatic prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Early use of abiraterone and radium-223 in metastatic prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents.
Topics: Aged; Androstenes; Antibodies, Antinuclear; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Prednisone; Prostatic Neoplasms | 2019 |
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fasting; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant | 2019 |
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Image-Guided Biopsy; Immunohistochemistry; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Drug Combinations; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment | 2019 |
Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Renal Dialysis | 2019 |
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable?
Topics: Adenocarcinoma; Androstenes; Carboxylic Acids; Combined Modality Therapy; Cyclobutanes; Gonadotropin-Releasing Hormone; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Irradiation; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms | 2020 |
Abiraterone acetate treatment lowers 11-oxygenated androgens.
Topics: Abiraterone Acetate; Adrenal Hyperplasia, Congenital; Adult; Androgens; Androstenes; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Drug Therapy, Combination; Humans; Male; Prednisone; Prostatic Neoplasms; Tandem Mass Spectrometry; Testosterone | 2020 |
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Topics: Abiraterone Acetate; Adult; Aged; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cohort Studies; Drug Administration Schedule; Health Care Costs; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2020 |
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials.
Topics: Androstenes; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Vitamin D | 2020 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
Topics: Androstenes; Antineoplastic Agents; Apoptosis; Bexarotene; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Mitochondria; Molecular Structure; Prednisone; Rhodamines; Structure-Activity Relationship; Testosterone | 2020 |
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Confidence Intervals; Cost-Benefit Analysis; Docetaxel; Humans; Male; Markov Chains; Monte Carlo Method; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Radiosurgery; Salvage Therapy; Time Factors | 2020 |
Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone.
Topics: Aged; Androstenes; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome | 2020 |
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Transcriptome | 2021 |
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Hypokalemia; Male; Paralysis; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2022 |
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms | 2022 |
Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Humans; Male; Neoplastic Cells, Circulating; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |